hotspot -WSS

hotspot

author：fashion 2025-09-06 03:58:17 - browse：6419

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

WSS

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Judge denies Trump's request for new trial in E. Jean Carroll case

A new ‘biological computer' targets cancer while sparing healthy cells

Telehealth startups are trying to fill the menopause care vacuum

Stanford president’s abrupt resignation sparks debate

Extensive review finds private equity owners jack up cost of care

leisure time

hotspot

hotspot

Alkermes shareholders re

There’s a way to spot data fakery. All journals should be using it

Walensky prepares to leave CDC — and Congress — behind

Mystery swirls around US soldier who entered North Korea days ago, officials say

Psychedelics group wrestles with new pharma identity

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

23andMe had bad news about my health. I wish a person had delivered it

'CMA Fest' 2023: How to watch, who is performing and more

knowledge

Dementia risk linked to living in disadvantaged areas: Study

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

'CMA Fest' 2023: How to watch, who is performing and more

A new ‘biological computer' targets cancer while sparing healthy cells

There’s a way to spot data fakery. All journals should be using it

Mystery swirls around US soldier who entered North Korea days ago, officials say

focus

entertainment

focus

Wikipedia